Gene and genetic diagnostic method patent claims: a comparison under current European and US patent law

Por Huys, Isabelle, Van Overwalle, Geertrui, Matthijs, Gert
Publicado em 2011

Drug shortages in European countries: a trade-off between market attractiveness and cost containment?

Por Pauwels, Kim, Huys, Isabelle, Casteels, Minne, Simoens, Steven
Publicado no BMC Health Serv Res (2014)

Insights into European Drug Shortages: A Survey of Hospital Pharmacists

Por Pauwels, Kim, Simoens, Steven, Casteels, Minne, Huys, Isabelle
Publicado no PLoS One (2015)

Qualitative study on custodianship of human biological material and data stored in biobanks

Por Verlinden, Michiel, Nys, Herman, Ectors, Nadine, Huys, Isabelle
Publicado no BMC Med Ethics (2016)

Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs

Por Pauwels, Kim, Huys, Isabelle, Casteels, Minne, Simoens, Steven
Publicado no Front Pharmacol (2016)

Toward a European definition for a drug shortage: a qualitative study

Por De Weerdt, Elfi, Simoens, Steven, Casteels, Minne, Huys, Isabelle
Publicado no Front Pharmacol (2015)

Innovative Medicines Initiative (IMI) Case Study Analysis Reveals the True Added Value of Early-Phase Public-Private Partnerships (PPPs)

Por Stevens, Hilde, Van Overwalle, Geertrui, Van Looy, Bart, Huys, Isabelle
Publicado no Biotechnol Law Rep (2015)

Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future

Por Pauwels, Kim, Huys, Isabelle, Vogler, Sabine, Casteels, Minne, Simoens, Steven
Publicado no Front Pharmacol (2017)

Time spent by Belgian hospital pharmacists on supply disruptions and drug shortages: An exploratory study

Por De Weerdt, Elfi, De Rijdt, Thomas, Simoens, Steven, Casteels, Minne, Huys, Isabelle
Publicado no PLoS One (2017)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies

Por Moorkens, Evelien, Jonker-Exler, Clara, Huys, Isabelle, Declerck, Paul, Simoens, Steven, Vulto, Arnold G.
Publicado no Front Pharmacol (2016)

Paving a regulatory pathway for phage therapy: Europe should muster the resources to financially, technically and legally support the introduction of phage therapy

Por Huys, Isabelle, Pirnay, Jean-Paul, Lavigne, Rob, Jennes, Serge, De Vos, Daniel, Casteels, Minne, Verbeken, Gilbert
Publicado em 2013

Call for a Dedicated European Legal Framework for Bacteriophage Therapy

Por Verbeken, Gilbert, Pirnay, Jean-Paul, Lavigne, Rob, Jennes, Serge, De Vos, Daniel, Casteels, Minne, Huys, Isabelle
Publicado em 2014

Financial based agreements and performance based agreements: the Belgian experience

Por Pauwels, Kim, Huys, Isabelle, Bielen, Eveline, Bormans, Sigrid, Vincken, Robin, Zheng, Henna, Casteels, Minne, Simoens, Steven
Publicado no J Pharm Policy Pract (2015)

Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations grante...

Por Pauwels, Kim, Huys, Isabelle, Casteels, Minne, Larsson, Kristina, Voltz, Caroline, Penttila, Karri, Morel, Thomas, Simoens, Steven
Publicado no Orphanet J Rare Dis (2017)

BmTx3, a scorpion toxin with two putative functional faces separately active on A-type K+ and HERG currents.

Por Huys, Isabelle, Xu, Chen-Qi, Wang, Cheng-Zhong, Vacher, Hélène, Martin-Eauclaire, Marie-France, Chi, Cheng-Wu, Tytgat, Jan
Publicado em 2004

Taking Bacteriophage Therapy Seriously: A Moral Argument

Por Verbeken, Gilbert, Huys, Isabelle, Pirnay, Jean-Paul, Jennes, Serge, Chanishvili, Nina, Scheres, Jacques, Górski, Andrzej, De Vos, Daniel, Ceulemans, Carl
Publicado em 2014

Business oriented EU human cell and tissue product legislation will adversely impact Member States’ health care systems

Por Pirnay, Jean-Paul, Vanderkelen, Alain, De Vos, Daniel, Draye, Jean-Pierre, Rose, Thomas, Ceulemans, Carl, Ectors, Nadine, Huys, Isabelle, Jennes, Serge, Verbeken, Gilbert
Publicado em 2013

Access to human tissues for research and product development: From EU regulation to alarming legal developments in Belgium

Por Pirnay, Jean-Paul, Baudoux, Etienne, Cornu, Olivier, Delforge, Alain, Delloye, Christian, Guns, Johan, Heinen, Ernst, Van den Abbeel, Etienne, Vanderkelen, Alain, Van Geyt, Caroline, van Riet, Ivan, Verbeken, Gilbert, De Sutter, Petra, Verlinden, Michiel, Huys, Isabelle, Cockbain, Julian, Chabannon, Christian, Dierickx, Kris, Schotsmans, Paul, De Vos, Daniel, Rose, Thomas, Jennes, Serge, Sterckx, Sigrid
Publicado no EMBO Rep (2015)

Quality and Safety Requirements for Sustainable Phage Therapy Products

Por Pirnay, Jean-Paul, Blasdel, Bob G., Bretaudeau, Laurent, Buckling, Angus, Chanishvili, Nina, Clark, Jason R., Corte-Real, Sofia, Debarbieux, Laurent, Dublanchet, Alain, De Vos, Daniel, Gabard, Jérôme, Garcia, Miguel, Goderdzishvili, Marina, Górski, Andrzej, Hardcastle, John, Huys, Isabelle, Kutter, Elizabeth, Lavigne, Rob, Merabishvili, Maia, Olchawa, Ewa, Parikka, Kaarle J., Patey, Olivier, Pouilot, Flavie, Resch, Gregory, Rohde, Christine, Scheres, Jacques, Skurnik, Mikael, Vaneechoutte, Mario, Van Parys, Luc, Verbeken, Gilbert, Zizi, Martin, Van den Eede, Guy
Publicado no Pharm Res (2015)

Biosimilars in Europe

Publicado em 2023